Myelodysplastic syndromes (MDS) are chronic and often progressive myeloid neoplasms associated with remarkable heterogeneity in the histomorphology and clinical course. Various somatic mutations are involved in the pathogenesis of MDS. Recently, mutations in a gene encoding a spliceosomal protein, SF3B1, were discovered in a distinct form of MDS with ring sideroblasts. Whole exome sequencing of 15 patients with myeloid neoplasms was performed and somatic mutations in spliceosomal genes were identified. Sanger sequencing of 310 patients was carried out to assess phenotype/genotype associations.
Introduction
The myelodysplastic syndromes (MDS) are characterized by clonal hematopoiesis, a variety of chromosomal abnormalities, bone marrow failure and a propensity for evolution to acute myeloid leukemia (AML). Because of their often protracted course, MDS recapitulate the stages of acquisition of a malignant phenotype, thereby offering insights into leukemogenesis. While traditionally, histomorphology-based schemes have been applied to sub-classify MDS patients, 1,2 this approach is unlikely to be reflective of the underlying pathogenesis. Instead, a better molecular characterization of MDS on the genomic, epigenetic and genetic levels is more likely to objectively diagnose patients, determine their prognosis and, based on the underlying molecular defects, direct the application of targeted therapies. The emerging realization of the molecular diversity of MDS parallels the clinical and phenotypic heterogeneity of this disease. Moreover, molecular defects have the potential to serve as biomarkers and are more likely to be suitable for the identification of therapy targets and responsiveness/refractoriness to treatment.
The application of high-throughput molecular technologies, including high density single nucleotide polymorphism arrays (SNP-A) 3 and new sequencing technologies 4, 5 has led to the improved characterization of genomic lesions such as chromosomal aberrations and of somatic mutations affecting specific classes of genes, 6 including signal transducers (e.g., CBL), [7] [8] [9] [10] apoptotic genes (e.g., TP53 and RAS), [11] [12] [13] genes involved in epigenetic regulation of DNA (e.g., DNMT3A, IDH1/2 and TET2) [14] [15] [16] [17] [18] and histone modifiers (e.g., EZH2, UTX and ASXL1). [19] [20] [21] [22] [23] [24] While some mutations in these factors are activating, most are loss of function or hypomorphic mutations and affect bona fide tumor suppressor genes (TSG). Of greatest diagnostic impact are recurrent mutations found in specific genes. Most TSG mutations are not canonical, though, making systematic clinical diagnostics more difficult.
We and other groups recently identified a variety of new mutations present at distinct frequencies in subgroups of MDS patients. 25, 26 Analogous to previously applied strategies that identified TET2, CBL, EZH2
and other mutations, 7, 18, 21 we have identified mutations affecting, in a recurrent fashion, genes of the spliceosome machinery, using a combination of targeted search approaches and unbiased mass sequencing. Such mutations likely constitute a new class of TSG ubiquitously involved in leukemogenesis.
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Methods

Patient population.
Bone marrow aspirates or blood samples were collected from 315 patients with MDS (N=88), MDS/myeloproliferative neoplasms (MDS/MPN, N=66), MPN (N=52), secondary AML (sAML) (N=54) that evolved from these conditions and primary AML (pAML) (N=55) seen at Cleveland Clinic or Nagoya University between 2003 and 2010 (Table 1) . Informed consent for sample collection was obtained according to protocols approved by the institutional IRBs and in accordance with the Declaration of Helsinki. 
Cytogenetics and single nucleotide polymorphism array (SNP-A) analyses.
Technical details regarding sample processing for SNP-A assays were previously described. 28 ,29 Affymetrix 250K and 6.0 Kit (Affymetrix, Santa Clara, CA) were used. A stringent algorithm was applied for the identification of SNP-A lesions. Patients with SNP-A lesions concordant with metaphase cytogenetics or typical lesions known to be recurrent required no further analysis. Changes reported in our internal or publicly-available (Database of Genomic Variants; http://projects.tcag.ca/variation) copy number variation (CNV) databases were considered non-somatic and excluded. Results were analyzed using CNAG (v3.0) 30 or Genotyping Console (Affymetrix). All other lesions were confirmed as somatic or germline by analysis of CD3-sorted cells. Whole exome sequencing.
Genomic DNA was extracted from bone marrow or peripheral blood using standard methods and subjected agarose gel and optical density ratio tests to confirm the purity and concentration prior to Covaris (Covaris, Inc., Woburn, MA) fragmentation. 0. Whole RNA deep sequencing.
Total RNA was extracted from bone marrow mononuclear cells using the Nucleospin RNA II Kit (MachereyNagel, Bethlehem, PA) with DNAase treatment. The integrity and purity of total RNA were assessed using Agilent Bioanalyzer. 1-2 μ g of cDNA was generated using Clontech SmartPCR cDNA kit (Clontech Laboratories, Inc., Mountain View, CA) from 100ng of total RNA. cDNA was fragmented using Covaris, profiled using Agilent Bioanalyzer, and subjected to Illumina library preparation using NEBNext reagents (New England Biolabs, Ipswich, MA). The quality and quantity and the size distribution of the Illumina libraries were determined using an Agilent Bioanalyzer. The libraries were then submitted for Illumina HiSeq2000 sequencing according to standard procedures. Paired-end 90 base pair reads were generated and subjected to data analysis using the platform provided by DNAnexus. DNAnexus software allowed 
Results
Detection of somatic spliceosomal mutations in myeloid malignancies.
Initially, we performed whole exome sequencing of 15 index cases with various forms of myeloid malignancies and identified distinct somatic mutations in genes encoding components of the spliceosomal machinery (Supplemental Table 1 ). A heterozygous missense mutation in U2AF1 (Q157R) was found in a patient with refractory cytopenia with unilineage dysplasia (RCUD) and uniparental disomy of 2q (UPD2q) ( Figure 1A ). Analysis of DNA from CD3 positive cells showed a much lower frequency of the base change Moreover, no homozygous mutations were found in patients with UPD21q (N=8). Similarly, all mutations of SF3B1 and SRSF2 were heterozygous, and patients with somatic UPD2q33.1 or UPD17q25 (regions containing SF3B1 and SRSF2, respectively) did not harbor homozygous mutations of the associated genes.
Clinical associations and frequencies of spliceosomal mutations in myeloid malignancies.
We subsequently screened a large cohort of patients (N=310) with MDS and related disorders (including the initially screened 120 cases) in a stepwise fashion to determine the frequency of spliceosomal mutations discovered in the index cases. Based on the initial screen, we noted that mutations in U2AF1, SF3B1 and SRSF2 were the most frequent. Consequently, we sequenced 120 cases for ZRSR2, LUC7L2 and PRPF8 and a total 310 for SF3B1, U2AF1, and SRSF2. All SF3B1 mutations were located in exon 14 or 15, with For personal use only. on July 16, 2017. by guest www.bloodjournal.org From the K700 mutation being the most recurrent ( Figure 1B) . Similarly, all mutations in SRSF2 affected position P95 ( Figure 1D ). In contrast, mutations in U2AF1 affected exons 2 and 6, corresponding to the 2 zinc finger domains of this protein ( Figure 1A, Supplemental Figure 3 ). The extended cohort of patients was used to identify phenotype/genotype associations (Supplemental Table 2 ). To avoid any misunderstanding, we included information as to which cases were analyzed by whole exome sequencing in Supplemental Table   2 . Additionally, in Supplemental Table 1 , we clarified the mutational status of spliceosomal genes. In lowrisk MDS, mutations of any one of these three genes were found in 39% of patients, and further analysis revealed that mutations in SF3B1 were highly associated with RARS. Among patients with MDS/MPN, SF3B1 mutations were not common in chronic myelomonocytic leukemia (CMML), but they were frequent in patients with RARS-T and thus the presence of RS was found to correlate highly with SF3B1 mutations, irrespective of other clinical or morphologic features (Figure 2A ). In contrast, U2AF1 mutations were most frequent in the high risk MDS/AML cohort (11%), while SRSF2 was most frequently mutated in MDS/MPN (24%) particularly in CMML (28%) (Figure 2A ).
Impact of spliceosomal mutations on clinical outcomes.
Subsequently, we studied the impact of the most common spliceosomal mutations on clinical outcomes. We first analyzed the entire cohort of patients (Table 1 ) and determined the survival of patients in whom the three most common spliceosomal mutations were present. We included the information as to SF3B1 mutation status of 39 cases reported in our previous paper. 32 When 310 patients genotyped for these mutations were analyzed, the presence of SF3B1 mutations was associated with longer survival, U2AF1
mutations with shorter survival, while SRSF2 mutations had no effect on survival. We then analyzed the impact of these mutations in more clinically uniform subgroups to more precisely determine their clinical consequences. As expected, in sAML and pAML, due to overall poor prognosis, the presence of spliceosomal mutations did not further affect survival (Supplemental Figure 4) . However, in low-risk MDS, patients with SF3B1 mutations showed a tendency towards better prognosis (p=.09), while those with SRSF2 mutations had worse survival. In MDS/MPN, SRSF2 mutations were more common than U2AF1;
however, U2AF1 mutations were associated with shorter survival ( Figure 2B ). When serial samples were analyzed, we found that an U2AF1 mutation detected at the sAML stage were present from initial MDS presentations, suggesting an ancestral origin of this mutation (Supplemental Figure 5) . Overall, SF3B1 mutations were less prevalent in patients with advanced forms of MDS, indicating that mutation of this factor does not contribute to progression (Figure 2A ).
Effects of spliceosomal mutations on spliceosomal function.
Conceptually, mutations of spliceosomal proteins could result in defective splicing, including intron retention, altered splice site recognition or altered alternative splicing. To determine the functional consequences of
For personal use only. on July 16, 2017. by guest www.bloodjournal.org From spliceosomal mutations on splicing, we performed whole mRNA deep sequencing. In the presence of functional spliceosomal machinery, sequencing reads are expected not to cross the intron/exon boundaries, and therefore should not contain any intronic sequences. We analyzed RNA sequencing results in patients with mutations in U2AF1 (N=3), SRSF2 (N=2), SF3B1 (N=2) and U2AF26 (N=1), as well as in a healthy controls and one MDS patient with a WT configuration of these genes. There was no genome-wide increase in intron retention observed in the mutant patients. However, we found a number of specific genes in which the splicing pattern was altered. For instance, U2AF1 mutations were associated with defective splicing of intron 5 of TET2 at both splice sites ( Figure 3A, Supplemental Figure 6 ), while splicing of other TET2 introns were less affected. Another gene in which splicing was affected was RUNX1. At both the 3' and 5' splice sites of RUNX1 intron 6, unspliced reads were more frequent than spliced reads ( Figure 3B ). Such a splicing abnormality was more prominent in cases with SRSF2 mutations but not detected in the cases with SF3B1 mutations or WT spliceosomal genes. Similarly, U2AF26 mutations resulted in an alteration of RUNX1 splicing (Supplemental Figure 7) . Moreover, alternative splicing analysis showed that exon 9 of FECH was skipped in U2AF1 mutant cases but not in U2AF1 WT cases, including those with SF3B1 mutations (Supplemental Figure 8) .
Discussion
In recent years, a number of somatic mutations have been associated with various myeloid malignancies, including MDS. [15] [16] [17] 19, 22 Systematic screening studies revealed that such mutations do not only occur as sole abnormalities, but are often found in combination, likely contributing to the phenotypic heterogeneity found in MDS. 5, 25, 26 During our search for new molecular lesions associated with MDS, we identified somatic mutations affecting various components of the spliceosomal machinery, similar to previous reports. [32] [33] [34] [35] [36] Until these recent results were obtained, spliceosomal dysfunction was only rarely associated with malignant transformation.
In our studies in myeloid malignancies, the most commonly affected spliceosomal genes included SF3B1, U2AF1 and SRSF2. While these mutations were common and found in a wide spectrum of myeloid diseases, some are strongly associated with specific phenotypic features, such as SF3B1 mutations with MDS or MDS/MPN with RS and SRSF2 mutations with CMML and advanced forms of MDS such as sAML and RA with excess blasts. Serial studies performed on patients from the initial diagnosis of low-risk MDS through subsequent transformation indicate that U2AF1 mutations may represent early ancestral events. A higher cross-sectional prevalence among advanced cases suggests that both U2AF1 and SRSF2 constitute high-risk defects. Indeed, U2AF1 and SRSF2 mutations were associated with worse survival in CMML and low-risk MDS, respectively. In contrast, SF3B1 mutations are associated with generally good prognosis, compatible with their association with RARS, which has a protracted clinical course. 34, 36 That these mutations were not overlapping and also not found in cases with other spliceosomal defects suggests that the effect of a spliceosomal mutation on myeloid malignancies might be inhibited by mutation in another factor or that they might not have a synergetic impact on leukemogenesis.
The prognostic impact of SF3B1 mutations has been investigated in several studies. While initial reports (354 patients) suggested SF3B1 mutations convey significantly longer OS, leukemia-free survival (LFS), and event-free survival in their cohort 34 , subsequent analysis of 323 MDS cases, patients carrying an SF3B1 mutation showed a significantly better OS and no effect on LFS in RARS and RCMD-RS; the "protective effect" of SF3B1 mutation on OS was lost in multivariate analysis including clinical variables such as International Prognostic Scoring System (IPSS) score. 36 Our results in the whole cohort of 310 MDS patients were generally consistent with these studies. However, we could not detect a significant difference in OS when subgroups with RS were analyzed separately, perhaps due to low number of WT cases. More recently, a large series of MDS patients (N=317) showed that the SF3B1 mutation status was not associated with time to AML progression or OS, regardless if all patients or only the subgroup of patients with RS were included in the analyses. 37 Similar results were reported for myelofibrosis. 38 When the survival benefit of SF3B1 mutations was examined in patients with MDS with increased RS, the Most of the mutations we detected were heterozygous, indicating that homozygous mutations may lead to cell death or that some of the functional consequences are related to dominant negative effects.
Other mutations, including those in LUC7L2, ZRSR2 and PRPF8, appear to be less prevalent and, due to the small number of positive cases within the already large cohort studied, we were unable to establish According to a recent report, knock down of U2AF1 expression leads to the skipping of a specific exon of FECH during splicing. 40 Based on the same phenomenon seen in alternative splicing analysis using mRNA deep sequencing of U2AF1 mutants, among the three most frequently mutated spliceosomal genes, U2AF1 mutations might result in loss of function. Further studies will clarify the whole alteration of mRNA splicing profiles induced by spliceosomal gene mutations.
Interestingly, spliceosome mutations, specific in SF3B1, were reported in chronic lymphocytic leukemia. [41] [42] [43] The discovery of recurrent somatic mutations in various genes encoding spliceosomal proteins indicates that spliceosomal defects constitute an important and ubiquitous pathway in malignant transformation. Further mutational screening in other malignancies might uncover the pathogenesis of common or unique tumorgenesis in various tissues.
The most relevant question, both biologically and clinically, is which other gene mutations are associated with the mutation status of individual spliceosomal genes. According to our preliminary results, U2AF1 mutations seem to be most commonly associated with ASXL1 and TET2 mutations, whereas SF3B1
can occur in the context of RUNX1 mutations (data not shown). Some presentations by other groups in ASH 2011 meeting suggested a correlation between SF3B1 and DNMT3A mutations 44,45 and a favorable survival impact of RUNX1 mutations in CMML with SRSF2. 46 Due to the large numbers of diverse mutations, very large studies will be needed to fully evaluate the correlation between the mutation status of spliceosomal genes and other genes in a proper fashion.
In sum, our studies demonstrate the wide-spread presence of mutations in genes involved in splicing in myeloid neoplasms. Such mutations may lead to distinct phenotypes and, because there is impact on survival, their detection may have future diagnostic utility. Conflict of interest disclosure: The authors declare no competing financial interests. For personal use only. on July 16, 2017. by guest www.bloodjournal.org From (A) In the entire cohort (N=310), a total of 88 mutations in the spliceosome pathway components U2AF1, SF3B1 and SRSF2 were observed in every subtype of myeloid malignancies, except for MPN. In low risk MDS, SF3B1 mutations were most frequent among the 3 genes. In particular, SF3B1 was mutated in 15/20 cases of RARS (60%). In the high risk MDS and AML group, U2AF1 mutations were most frequent (15/139; 10.8%). In the MDS/MPN group, SRSF2 was most frequently mutated (13/46; 28.2%), while SF3B1 is mutated at a high frequency in RARS-T (10/11; 90.1%). (B) Impact of spliceosomal mutations on clinical outcomes. In the entire cohort, patients with U2AF1 mutations (MT) had worse overall survival (OS), compared with wild type (WT), but SF3B1 mutations made OS significantly shorter. In low risk MDS, mutation of SF3B1 was a good prognostic factor but SRSF2 mutations are associated with worse prognosis.
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